Celcuity Inc. (NASDAQ:CELC) Short Interest Up 11.4% in September

Celcuity Inc. (NASDAQ:CELC) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 2,550,000 shares, a growth of 11.4% from the August 31st total of 2,290,000 shares. Based on an average daily volume of 416,400 shares, the short-interest ratio is currently 6.1 days.

Celcuity Price Performance

CELC traded up $0.16 during trading on Friday, hitting $14.40. The company’s stock had a trading volume of 101,975 shares, compared to its average volume of 291,706. The firm has a market capitalization of $505.45 million, a price-to-earnings ratio of -5.18 and a beta of 0.76. Celcuity has a twelve month low of $8.39 and a twelve month high of $22.19. The business’s fifty day simple moving average is $16.27 and its 200 day simple moving average is $16.75. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period last year, the company earned ($0.66) earnings per share. On average, equities research analysts forecast that Celcuity will post -2.54 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Lifesci Capital initiated coverage on shares of Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. Stifel Nicolaus reduced their target price on Celcuity from $40.00 to $39.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Thursday, August 15th. HC Wainwright restated a “buy” rating and set a $27.00 price target on shares of Celcuity in a research note on Thursday, August 15th. Finally, Leerink Partners initiated coverage on shares of Celcuity in a report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective on the stock. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Celcuity presently has an average rating of “Buy” and an average target price of $28.67.

Hedge Funds Weigh In On Celcuity

Several large investors have recently made changes to their positions in CELC. Commodore Capital LP raised its position in Celcuity by 3.6% in the fourth quarter. Commodore Capital LP now owns 1,754,704 shares of the company’s stock valued at $25,566,000 after purchasing an additional 60,563 shares during the period. Baker BROS. Advisors LP raised its holdings in shares of Celcuity by 189.9% in the 1st quarter. Baker BROS. Advisors LP now owns 1,552,478 shares of the company’s stock valued at $33,534,000 after buying an additional 1,017,000 shares during the period. Perceptive Advisors LLC acquired a new position in Celcuity during the 4th quarter worth about $21,583,000. Samlyn Capital LLC boosted its holdings in Celcuity by 92.4% during the 2nd quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after acquiring an additional 637,190 shares during the period. Finally, Vanguard Group Inc. grew its position in Celcuity by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 828,597 shares of the company’s stock valued at $17,898,000 after acquiring an additional 7,821 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors and hedge funds.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.